Avion Pharmaceuticals announced the launch of Gloperba (colchicine) oral solution for prophylaxis of gout flares in adults.
Gloperba is a ready-to-use solution for oral administration containing 0.12mg/mL of colchicine. The approval was based on evidence from published literature supporting the efficacy of colchicine in patients with chronic gout. In 2 randomized clinical trials, treatment with colchicine 0.6mg twice daily was associated with a decrease in the frequency of gout flares.
The safety and efficacy of Gloperba for acute treatment of gout flares during prophylaxis has not been studied. It should not be used to treat pain from other causes.
The product is supplied in 150mL bottles.
“Gloperba brings a new level of flexibility and control to the management of gout with colchicine,” said Art Deas, CEO of Avion Pharmaceuticals. “As a liquid, Gloperba gives physicians the power to easily individualize treatment and titrate dosing based on their patients’ unique needs.”
For more information visit gloperba.com.
This article originally appeared on MPR